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Aims The high costs associated with treatment for atrial fibrillation (AF) are primarily due to hospital care, but there are
limited data to understand the reasons for and predictors of hospitalization in patients with AF.
Methods and
results
The ROCKET AF trial compared rivaroxaban with warfarin for stroke prophylaxis in AF. We described the frequency of
and reasons for hospitalization during study follow-up and utilized Cox proportional hazards models to assess for base-
line characteristics associated with all-cause hospitalization. Of 14 171 patients, 14% were hospitalized at least once. Of
2614 total hospitalizations, 41% were cardiovascular including 4% for AF; of the remaining, 12% were for bleeding.
Compared with patients not hospitalized, hospitalized patients were older (74 vs. 72 years), and more frequently
had diabetes (46 vs. 39%), prior MI (23 vs. 16%), and paroxysmal AF (19 vs. 17%), but less frequently had prior transient
ischaemic attack/stroke (49 vs. 56%). After multivariable adjustment, lung disease [hazard ratio (HR) 1.46, 95% confi-
dence interval (CI) 1.29–1.66], diabetes [1.22, (1.11–1.34)], prior MI [1.27, (1.13–1.42)], and renal dysfunction [HR
1.07 per 5 unit GFR , 65 mL/min, (1.04–1.10)] were associated with increased hospitalization risk. Treatment assign-
ment was not associated with differential rates of hospitalization.
Conclusion Nearly 1 in 7 of the moderate-to-high-risk patients with AF enrolled in this trial was hospitalized within 2 years, and both
AF and bleeding were rare causes of hospitalization. Further research is needed to determine whether care pathways
directed at comorbid conditions among AF patients could reduce the need for and costs associated with hospitalization.
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Introduction
The prevalence of atrial fibrillation (AF) is high. In the USA alone, AF
affects between 3 and 6 million people, and this number is expected
to rise considerably by 2050.1 – 3 The economic burden associated
with treating patients with AF is substantial. Estimated annual
medical costs for patients with AF in the USA are 73% higher
than medically matched controls, primarily due to inpatient care
for conditions other than AF.4 In the UK, total expenditures
for AF have nearly doubled over the past 5 years, and more than
half of these costs are due to inpatient care.5 Given this growing
economic burden, it is important to understand the reasons for
hospitalization and factors associated with hospitalization in patients
with AF.
* Corresponding author: Tel: +919 668 8246; fax: +919 681 9842. E-mail address: adam.devore@duke.edu
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We utilized data from ROCKET AF (Rivaroxaban Once Daily
Oral Direct Factor Xa Inhibition Compared with Vitamin K Antag-
onism for Prevention of Stroke and Embolism Trial in Atrial Fibrilla-
tion)6 to (1) assess the rates of and reasons for hospitalization of
patients with AF and (2) determine patient factors associated with
hospitalization.
Methods
The design of the ROCKET AF study has been previously described.7
Briefly, ROCKET AF was a multinational, randomized, double-blind,
active-controlled trial of fixed-dose rivaroxaban vs. adjusted-dose
warfarin for the prevention of stroke in patients with nonvalvular AF
at moderate to high risk for stroke. The trial was designed to determine
whether rivaroxaban was noninferior to warfarin for the primary end-
point of stroke or non-central nervous system (CNS) systemic embol-
ism. The trial was conducted from December 2006 through May 2010 at
1178 participating sites in 45 countries and included 14 264 patients.
Qualifying medical history included a history of stroke, transient ischae-
mic attack (TIA), or systemic embolism or at least two of the following
risk factors: heart failure or a left ventricular ejection fraction of ≤35%,
hypertension, age ≥75 years, or the presence of diabetes mellitus (i.e. a
CHADS2 score of ≥2), and according to the protocol, patients with
only 2 risk factors were capped at 10% of the overall trial population,
with the remaining patients requiring ≥3 risk factors (CHADS2 ≥ 3)
or a prior stroke, TIA, or systemic embolism.
Patients were followed for the duration of the study to ascertain
clinical events. An independent clinical endpoint committee adjudicated
all suspected cases of stroke, systemic embolism, myocardial infarction,
death, and bleeding events. Detailed definitions of these study endpoints
were previously published.6 Patients were also evaluated at post-
randomization study visits at 1, 2, and 4 weeks, and every month there-
after. As part of the study visits, a standardized questionnaire was used
to query patients about emergency department visits and all-cause hos-
pitalizations. Details regarding dates, location, and reasons for hospital-
ization were recorded. If a reason for hospitalization was not apparent
from adjudication or recorded in the database, then adverse events
occurring 0–3 days before the hospitalization date were reviewed to
determine a cause of hospitalization. Patients were followed for a
median of 707 days, and only 32 patients were lost to follow-up.
The present study is a post hoc analysis of all patients randomized in
the trial (intention to treat). We assessed baseline characteristics and
future unplanned hospitalizations. Reasons for hospitalization were
broadly classified as bleeding, acute coronary syndrome, congestive
heart failure, stroke/TIA, non-CNS embolism, other cardiovascular,
and other.
The study conformed to the principles outlined in the Declaration of
Helsinki and was approved by each participating centre’s ethics commit-
tee or institutional review board. All patients provided written informed
consent prior to randomization, and all study participants gave informed
consent. The Duke Clinical Research Institute (Durham, NC) coordi-
nated the trial and performed the statistical analyses for this study.
The Institutional Review Board of the Duke University Health System
approved this study.
Statistical methods
We summarized patient characteristics stratified by hospitalizations.
Continuous variables were reported as medians and 25th and 75th per-
centiles; categorical variables were reported as counts and percentages.
We also summarized the number of hospitalizations during study
follow-up and stratified by region, broadly grouping into the following
regions of interest: Latin America, Eastern Europe, East Asia, Western
Europe, and North America. We tested for differences between the re-
gions using x2 tests for categorical variables and the Kruskal–Wallis
tests for continuous variables.
We used Cox proportional hazards models to assess for baseline
characteristics associated with risk of all-cause and cardiovascular hos-
pitalizations. Baseline characteristics including demographic data, treat-
ment assignment, and medical history were considered as candidate
variables for the models with the exception of CHADS2 score, which
was excluded due to concerns of colinearity. Continuous variables
were evaluated for linear associations with outcomes and modifications
(such as linear splines or truncations) were made when necessary. The
outcomes were time to first all-cause hospitalization and time to first
cardiovascular hospitalization. Forward stepwise selection was used
to determine final variables utilized in the model. The final model
included patients with complete data, and no missing data were im-
puted. Hazard ratios (HRs) [with 95% confidence interval (CI)] and
P-values are presented. P-values ,0.05 were considered statistically
significant.
Results
Of 14 264 patients randomized in ROCKET AF, 93 (0.7%) were
excluded due to violations in Good Clinical Practice guidelines at
one site.
Patient characteristics
Of the 14 171 evaluable patients, 1925 (14%) were hospitalized at
least once, and 474 of 1925 (25%) patients were hospitalized
more than once. Characteristics of the patients stratified by hospi-
talizations during follow-up are shown in Table 1. Patients with no
hospitalizations, compared with the other groups, were less likely
to have a history of a prior myocardial infarction, diabetes, and
chronic obstructive pulmonary disease (COPD). While history of
heart failure was similar in all groups, baseline use of a diuretic
was lower in patients with no hospitalizations compared with the
other groups.
What’s new?
† To our knowledge, this is the first study to describe and com-
pare hospitalizations in patients with atrial fibrillation (AF) in a
multinational dataset.
† We found that nearly 1 of 7 patients enrolled in the ROCKET
AF trial was hospitalized at least once within 2 years.
† The reasons for hospitalization were roughly split between
cardiovascular and non-cardiovascular causes, and both AF
and bleeding were rare causes of hospitalization.
† Patients in North America had the highest rate of hospitaliza-
tion, and factors associated with hospitalization included age
and comorbid conditions.
† This study has important implications for providers and inves-
tigators considering interventions aimed at reducing AF
hospitalizations.
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A summary of hospitalizations during study follow-up are shown in
Table 2, and reasons for hospitalization are displayed in Figure 1.
Over a median follow-up of 22 months (25th, 75th percentile 16,
28), there were a total of 2614 hospitalizations. The median number
was 1 (25th, 75th percentile 1, 1), and the overall range was from 1
to 9 hospitalizations per patient. There were a total of 2614 hospi-
talizations or 10.2 hospitalizations per 100 patient-years.
Cardiovascular causes (acute coronary syndrome, congestive
heart failure, TIA, stroke, and other cardiovascular) were the pri-
mary reason for hospitalization in 41% of cases. Bleeding was the
primary cause of hospitalization 12% of the time. Atrial fibrillation
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Table 1 Baseline characteristics of patients stratified by hospitalizations
All patients
(N 5 14 171)
No hospitalizations






Age, years 73 (65, 78) 72 (65, 78) 74 (67, 79) 75 (67, 79)
Female 40% (5605) 40% (4904) 37% (532) 36% (169)
Medical history
AF
New onset 1% (196) 1% (170) 1% (15) 2% (11)
Paroxysmal 18% (2490) 17% (2128) 18% (259) 22% (103)
Persistent 81% (11 485) 81% (9948) 81% (1177) 76% (360)
CHADS2 score, mean (SD) 3.5 (0.9) 3.5 (0.9) 3.5 (1.0) 3.5 (1.0)
1 ,1% (3) ,1% (3) 0 0
2 13% (1857) 13% (1540) 16% (234) 18% (83)
3 44% (6169) 44% (5401) 41% (591) 37% (177)
4 29% (4067) 29% (3547) 26% (383) 29% (137)
5 13% (1797) 13% (1532) 14% (203) 13% (62)
6 2% (278) 2% (223) 3% (40) 3% (15)
Prior stroke, TIA, or non-CNS embolism 55% (7767) 56% (6826) 50% (723) 46% (218)
Carotid artery disease 4% (589) 4% (469) 6% (88) 7% (32)
Congestive heart failure 62% (8851) 62% (7645) 62% (899) 65% (307)
Prior myocardial infarction 17% (2446) 16% (2003) 22% (316) 27% (127)
Peripheral arterial disease 6% (832) 6% (687) 7% (104) 9% (41)
Diabetes 40% (5647) 39% (4768) 46% (879) 46% (879)
Hypertension 90% (12 824) 90% (11 077) 91% (1317) 91% (430)
COPD 10% (1481) 10% (1172) 15% (214) 20% (95)
Baseline medications
Prior aspirin 37% (5184) 36% (4456) 38% (545) 39% (183)
Prior vitamin K antagonist 62% (8853) 61% (7510) 69% (1007) 71% (336)
ACE-I/ARB 74% (10 528) 74% (9071) 75% (1091) 77% (366)
b-Blocker 65% (9184) 64% (7877) 68% (993) 66% (314)
Digitalis 39% (5460) 38% (4685) 40% (576) 42% (199)
Diuretic 60% (8441) 58% (7121) 68% (980) 72% (340)
Baseline evaluation
Body mass index, kg/m2 28 (25, 32) 28 (25, 32) 28 (25, 32) 28 (25, 33)
Heart rate, beats per minute 76 (67, 86) 76 (68, 86) 75 (66, 85) 75 (66, 86)
Systolic blood pressure, mm Hg 130 (120, 140) 130 (120, 140) 130 (120, 140) 130 (120, 140)
Creatinine clearance,a mL/min 67 (52, 87) 68 (53, 87) 64 (49, 85) 63 (48, 87)
Left ventricular EF , 40% 23% (2497) 22% (2083) 26% (304) 28% (110)
Treatment assignment
Rivaroxaban 50% (7081) 50% (6105) 50% (732) 51% (244)
Continuous variables are shown as median (25th, 75th percentiles).
ACE-I, angiotensin-converting enzyme inhibitor; ARB, angiotensin II receptor blocker; CNS, central nervous system; COPD, chronic obstructive pulmonary disease; EF, ejection
fraction; SD, standard deviation; TIA, transient ischaemic attack.
aCreatinine clearance was calculated with the use of the Cockcroft–Gault formula.
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was the cause 4% of the time and is included under other cardiovas-
cular causes. The largest reason was ‘other’ and including diagnoses
such as pneumonia, COPD, and urinary tract infections. The com-
plete list of other causes is listed in the Supplementary material
online, Table. Time to first hospitalization by cause is displayed in
Figure 2. The median time to first hospitalization was 181 days
(25th, 75th percentile, 70, 391).
Hospitalizations by geographic region
The frequency and distribution of hospitalizations stratified by geo-
graphic region are shown in Table 3. Patients in Latin American and
Eastern Europe were least likely to have a hospitalization, and pa-
tients in North America were most likely to have a hospitalization
(P , 0.0001). In contrast, median hospital length of stay was longest
in Latin American and Eastern Europe and shortest in North
America (P , 0.0001).
Factors associated with all-cause and
cardiovascular hospitalizations
Patient factors associated with all-cause hospitalization are displayed
in Table 4. Geographic region was independently associated with
all-cause hospitalization with patients in Canada and USA having a
higher hazard for hospitalization compared with Latin America
(HR 0.53, 95% CI 0.44–0.64) and Eastern Europe (HR 0.64, 95%
CI 0.56–0.74). Comorbid conditions were independently asso-
ciated with increased risk of all-cause hospitalization including
chronic lung disease (HR 1.46, 95% CI 1.29–1.66), diabetes (HR
1.22, 95% CI 1.11–1.34), prior myocardial infarction (HR 1.27,
95% 1.13–1.42), and impaired renal function (HR 1.07 per 5 unit de-
crease in creatinine clearance below 65 mL/min, 95% CI 1.04–1.10),
and diuretic use (HR 1.37, 95% CI 1.24–1.52) was also independent-
ly associated with at least one hospitalization during follow-up.
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Table 2 Summary of hospitalizations during study
follow-up
Frequency
Patients with at least one hospitalization
during follow-up
14% (1925)
Days to first hospitalization, median
(25th, 75th percentile)
181 (70 391)








Median (25th, 75th percentile) 1 (1, 1)
Total number of all-cause hospitalizations 2614
Total all-cause hospitalizations






included a variety of causes
including pneumonia (5%),
















Figure 1 Reasons for hospitalization during study follow-up. This figure displays the reasons for hospitalization among all hospitalizations
(N ¼ 2614). Atrial fibrillation accounted for 109 of 2614 (4%) total hospitalizations and is included under other cardiovascular causes. The reasons
for other non-cardiovascular reasons are described in the Supplementary material online, Table. CNS, central nervous system; COPD, chronic
obstructive pulmonary disease; TIA, transient ischaemic attack; UTI, urinary tract infection.
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Randomized treatment (rivaroxaban vs. warfarin) was not asso-
ciated with differential rates of hospitalization (P ¼ 0.45). All-cause
hospitalization rates by selected comorbid conditions are displayed
in Figure 3. Patient factors associated with cardiovascular hospitaliza-
tions are displayed in Table 5.
Discussion
The economic burden associated with treating AF is substantial and
primarily due to hospital care.4,8 In this study, we assessed reasons
for hospitalization and factors associated with hospitalization in pa-
tients with AF. To our knowledge, this is the first study to describe
and compare AF hospitalizations in a multinational dataset. We
found nearly 1 of 7 patients enrolled in the trial was hospitalized
at least once within 2 years. The reasons for hospitalization were
roughly split between cardiovascular and non-cardiovascular causes,
and both AF and bleeding were rare causes of hospitalization.
Patients in North America had the highest rate of hospitalization
and factors associated with hospitalization included age and
comorbid conditions.
Our study builds upon previous work on hospitalization in pa-
tients with AF. In a previous analysis of registry data of exclusively
US patients, the rate of hospitalization was 31% annually, and
comorbid conditions (heart failure, COPD, and diabetes) were
associated with increased hazards for all-cause hospitalization.9
Our data confirm these findings in a multinational dataset. In a sep-
arate analysis of Medicare patients aged ≥65 years, 34% of patients








































































Figure 2 Time to first hospitalization. This figure displays the time to first hospitalization stratified by type of hospitalization. TIA, transient
ischaemic attack.
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N 1878 5407 2109 2096 2681
At least one hospitalization 9% (164) 10% (546) 15% (318) 17% (358) 20% (539) ,.0001
Days hospitalized per year, mean (SD) 0.9 (10.9) 1.0 (8.3) 1.4 (8.9) 1.6 (11.7) 1.4 (7.5) ,0.0001
Hospital length of stay, median (25th, 75th percentile) 7 (4, 12) 9 (6, 13) 6 (4, 10) 6 (4, 10) 5 (3, 8) ,0.0001
SD, standard deviation.
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cardiovascular and non-cardiovascular reasons listed as the primary
diagnoses code.10 The higher rates of hospitalization seen in these
two studies compared with ours likely reflect the increased use of
hospital-based care for patients with AF in the USA.
The geographic variability for both hospitalization and lengths of
stay observed in our study suggests that more work should be done
to understand international differences in care and outcomes for
patients with AF. To our knowledge, this has not been previously
described for AF care, though geographic variability in lengths of
stay and outcomes has been observed in other chronic diseases re-
quiring hospital-based care, including heart failure.11 The reasons for
geographic variability in our study are not apparent from our data
but could be related to differences in patient characteristics or
care delivery models. Further research should evaluate these
geographic differences to determine if the value of healthcare could
be improved in the USA with better outpatient care delivery mod-
els. These data also have implications for the design and interpret-
ation of future multinational clinical trials of patients with AF that
may include hospitalization as an endpoint.
Given the important overlap between AF and heart failure12 and
the frequent use of hospital-based care for patients with heart fail-
ure,13 it was somewhat surprising that heart failure was not asso-
ciated with hospitalizations in our study. However, chronic
diuretic use was associated with hospitalizations in our study, and
previous studies suggest that doses of diuretics are important mar-
kers of heart failure severity.14 Diuretic use in our study may be a
marker of heart failure severity and concomitant renal dysfunction.
We also found that randomized treatment assignment (rivaroxaban
vs. warfarin) was not associated with differential rates of hospitaliza-
tion. Whether these findings can be extended to patients outside of
clinical trials or lower-risk populations remains unclear.
This study has important implications for providers and
investigators considering interventions aimed at reducing AF
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Table 4 Baseline patient characteristics associated
with all-cause hospitalization
x2 HR (95% CI) P-value
Geographic region (reference ¼ Canada/US)
Latin America 108.70 0.53 (0.44, 0.64) ,0.0001
Eastern Europe 0.64 (0.56, 0.74)
Western Europe 1.05 (0.91, 1.20)
East Asia 1.04 (0.89, 1.21)
COPD 35.94 1.46 (1.29, 1.66) ,0.0001
Baseline diuretic use 35.91 1.36 (1.23, 1.51) ,0.0001
Creatinine clearance, per
5-unit decrease below 65a
25.90 1.07 (1.04, 1.10) ,0.0001
SBP, per 5-mmHg decrease
below 120b
18.21 1.08 (1.04, 1.13) ,0.0001
Diabetes 17.38 1.22 (1.11, 1.34) ,0.0001
Prior myocardial infarction 16.91 1.27 (1.13, 1.42) ,0.0001
Prior aspirin use 12.39 1.21 (1.09, 1.34) 0.0004
BMI, per 1 unit increase
above 31c
9.79 1.02 (1.01, 1.03) 0.0018
Age, per 5 year increase 8.78 1.05 (1.02, 1.08) 0.0030
Prior use of vitamin K
antagonist
7.43 1.18 (1.05, 1.32) 0.0064
Male 6.14 1.13 (1.03, 1.25) 0.013
Carotid artery disease 5.38 1.25 (1.04, 1.51) 0.020
Heart rate, per 5 bpm
increase above 90d
4.82 1.04 (1.00, 1.08) 0.028
BMI, body mass index; SBP, systolic blood pressure; US, United States.
aFor creatinine clearance, there was equivalent risk for all values ≥65 mL/min.
bFor SBP, there was equivalent risk for all values ≥120 mmHg.
cFor BMI, there was equivalent risk for all values ≤31 kg/m2.



































COPD CHF CKD Diabetes Prior stroke/TIA Prior MI
Condition present
Condition absent
Figure 3 Hospitalization rates by the presence or absence of selected comorbid conditions. This figure displays the all-cause hospitalization rate
per 100 patient-years by selected comorbid conditions. Patients may have more than one comorbid condition and be included in this figure.
COPD, chronic obstructive pulmonary disease; CHF, congestive heart failure; CKD, chronic kidney disease as is defined by a creatinine clearance
,60 mL/min calculated with the use of the Cockcroft–Gault formula; TIA, transient ischaemic attack; MI, myocardial infarction.
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hospitalizations. For example, a clinical trial of nurse-led care for
outpatients with AF from the Netherlands demonstrated reduced
cardiovascular hospitalizations and cardiovascular mortality com-
pared with usual care,15 and a recent clinical trial of a nurse-led
disease management programme for patients with AF recently dis-
charged from the hospital in Australia demonstrated more days alive
and out of the hospital compared with usual care.16 Both of these
interventions focused on AF-specific care, such as providing and
educating patients on guideline-directed medical therapy for AF17
or improving risk assessment to improve antithrombotic treat-
ments.18 These interventions may be enhanced and treatment
effects improved by incorporating elements of disease management
for comorbid conditions that are associated with hospitalizations,
such as chronic pulmonary disease.
This study also has significant policy implications for providers
and payers considering bundled payments and/or reimbursement
penalties for patients with AF. A large proportion of hospitalizations
related to AF are attributable to non-cardiovascular causes and AF-
specific hospitalizations and hospitalizations due to bleeding while
on anticoagulation were relatively uncommon. Further research is
needed to determine whether care pathways directed at coexisting
pulmonary disease, diabetes, and impaired renal function among
patients with AF could reduce the need for and the costs associated
with hospitalization.
Limitations
The data for this study are derived from patients enrolled in the
ROCKET AF trial with specific eligibility criteria and thus may not
be generalizable to other patient populations. The reasons for hos-
pitalization were not adjudicated for all medical conditions, but an
independent clinical endpoint committee adjudicated all suspected
cases of stroke, systemic embolism, myocardial infarction, death,
and bleeding events. The treatments administered during the hospi-
talization or level of acuity was not recorded as part of study follow-
up. Residual measured or unmeasured confounding may impact
some of our findings.
Conclusions
Nearly 1 of 7 of the moderate-to-high-risk ambulatory patients with
AF in this trial was hospitalized within 2 years. The most common
causes were cardiovascular related, but approximately half were
for other medical conditions. Bleeding and AF were uncommon
causes of hospitalization. Programmes and care pathways designed
to reduce hospitalizations and healthcare expenditures in a similar
moderate-to-high-risk population need to consider a variety of
co-morbid medical conditions.
Supplementary material
Supplementary material is available at Europace online.
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Table 5 Baseline patient characteristics associated
with cardiovascular hospitalization
x2 HR (95% CI) P-value
Creatinine clearance, per 5
unit decrease below 60a
44.11 1.13 (1.09, 1.18) ,0.0001
Prior myocardial infarction 34.21 1.58 (1.35, 1.84) ,0.0001
Geographic region (reference ¼ Canada/US)
Latin America 31.62 0.58 (0.44, 0.76) ,0.0001
Eastern Europe 0.81 (0.67, 0.96)
Western Europe 1.17 (0.96, 1.43)
East Asia 0.86 (0.68, 1.08)
Diabetes 19.66 1.36 (1.19, 1.55) ,0.0001
SBP, per 5 mmHg decrease
below 125b
12.75 1.08 (1.04, 1.13) 0.0004
Baseline diuretic use 10.57 1.28 (1.10, 1.48) ,0.0001
Baseline b-blocker 8.04 1.24 (1.07, 1.44) 0.0046
Prior aspirin use 4.89 1.17 (1.02, 1.34) 0.027
COPD 4.57 1.24 (1.02, 1.50) 0.032
SBP, systolic blood pressure; US, United States.
aFor creatinine clearance, there was equivalent risk for all values ≥60 mL/min.
bFor SBP, there was equivalent risk for all values ≥125 mmHg.
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